In welcome news for suffers of knee-related osteoarthritis (OA), Paradigm Biopharmaceuticals Ltd (ASX:PAR) may have demonstrated a way to slow progression.
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is increasing its presence at and participation in the Osteoarthritis Research Society International (OARSI) 2023.
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has randomised its first UK subject and kicked off dosing in the pivotal PARA OA 002 phase 3 study, evaluating.
The ASX rose sharply today, despite the Reserve Bank of Australia once again hiking interest rates. The S&P/ASX200 gained 228.50 points or 3.54% to 6,685.40.